Ayala Pharmaceuticals

Ayala Pharmaceuticals is a clinical-stage oncology company dedicated to developing small molecule therapies for patient populations suffering from rare or aggressive cancers. Ayala's approach focuses on predicting, identifying, and addressing the oncogenic drivers of cancer by combining its bioinformatics platform with next-generation sequencing, thereby providing targeted therapeutic options for patient groups.Ayala Pharmaceuticals is committed to developing drugs for genetically and clinically rare cancers. The company leverages knowledge from bioinformatics and functional biology to create a Notch-centered patient identification engine. Currently, Ayala Pharmaceuticals is developing two candidate products, AL101 and AL02, for two rare and aggressive tumors. The goal is to treat various cancers by inhibiting the abnormal activation of the Notch pathway through γ-secretase inhibitors, including adenoid cystic carcinoma, triple-negative breast cancer, T-cell acute lymphoblastic leukemia, glioma, and multiple myeloma (in collaboration with Novartis).